Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease
31. Juli 2024 09:00 ET
|
Vaccinex, Inc.
Positive data for SIGNAL-AD trial of Pepinemab in Alzheimer’s Disease affirm expectation of a novel mechanism to delay progression of Alzheimer’s disease
Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease at the Alzheimer’s Association International Conference, Philadelphia, July 31, 2024
17. Juli 2024 08:00 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., July 17, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s disease (AD) and...
Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rule
04. Dezember 2023 08:00 ET
|
Vaccinex, Inc.
Company Has Reassured Nasdaq of Actions It Plans to Take to Meet Minimum Bid Price Requirement Randomized Phase 2 Study in Alzheimer’s Disease on Schedule to Complete Treatment in June 2024 ...
Konica Minolta Raises $125,000 for Alzheimer’s Research
24. Oktober 2023 10:37 ET
|
Konica Minolta Business Solutions U.S.A., Inc.
Ramsey, NJ, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Konica Minolta Business Solutions U.S.A., Inc. (Konica Minolta) today announced the final fundraising results through its participation in the...
Vaccinex, Inc. to Participate in the Jefferies Healthcare Conference Track 6, on Friday, June 9, 2023 at 10:00 to 10:25 a.m. ET
01. Juni 2023 08:00 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., June 01, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease...
Vaccinex Completes Enrollment in Phase 1b/2 SIGNAL-AD (Alzheimer’s Disease) Study of Pepinemab
25. April 2023 08:00 ET
|
Vaccinex, Inc.
Topline data anticipated in mid-2024 SIGNAL-AD builds on promising data from the Phase 2 SIGNAL Study in Huntington’s Disease ROCHESTER, N.Y., April 25, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc....
Vaccinex Announces $3.8 Million Private Placement
28. November 2022 08:00 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...
Konica Minolta Raises $97,000 for Alzheimer’s Research
06. Oktober 2022 15:32 ET
|
Konica Minolta Business Solutions U.S.A., Inc.
Ramsey, NJ, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Konica Minolta Business Solutions U.S.A., Inc. (Konica Minolta) today announced the final fundraising results through its participation in the...
Help Dixie Belle Paint Raise Up to $15,000 for the Fight Against Alzheimer's.
06. September 2022 15:00 ET
|
Dixie Belle Paint
PORT RICHEY, Fla., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Help Dixie Belle Paint raise up to $15,000 for the fight against Alzheimer's. Visit Dixie Belle on Facebook at Dixie Belle Paint Company and...
Vaccinex, Inc. Announces Presentation at the 2022 Alzheimer’s Association International Conference Updating the SIGNAL-AD Study of Pepinemab in Patients with Alzheimer’s Disease
29. Juli 2022 07:00 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., July 29, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...